Merck has entered into an agreement with Insmed, Inc. to purchase its portfolio of follow-on biologic therapeutic candidates and its commercial manufacturing facilities in Boulder, CO for $130 million in cash. “Insmed’s pipeline of follow-on biologic candidates presents the opportunity to expedite Merck’s entry into the biologics marketplace as well as providing unique manufacturing resources and an experienced team of protein experts,” said Frank K. Clyburn senior vi...